FDA approves first gene therapy for pediatric Sanfilippo syndrome

The US Food and Drug Administration granted accelerated approval to Fayuvi (rebisufligene etisparvovec-hopf), establishing the first available genetic treatment for pediatric patients with mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). The fatal lysosomal storage disorder stems from mutations in the SGSH gene, leading to severe neurocognitive decline and loss of motor function, usually resulting in death during adolescence.

The single-dose therapy uses an engineered adeno-associated virus vector to deliver a functional copy of the SGSH gene directly to systemic tissues and the central nervous system. Clinical trial data demonstrated a statistically significant reduction in heparan sulfate accumulations within cerebrospinal fluid, arresting cognitive deterioration when administered before irreversible tissue damage occurs.

This approval demonstrates that irreversible neurological decline can be arrested when caught early. Review your family pedigree for hereditary metabolic anomalies, and treat routine newborn genetic screening panels as primary preventive baselines rather than optional paperwork.